- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AZD 1080 | AZD-1080 | KB-160506
Compound class: Synthetic organic
Comment: AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, investigated in Phase I clinical trial for Alzheimer's disease. Development was subsequently discontinued.
This compound was in the AstraZeneca/MRC repurposing list from 2011
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Georgievska B, Sandin J, Doherty J, Mörtberg A, Neelissen J, Andersson A, Gruber S, Nilsson Y, Schött P, Arvidsson PI et al.. (2013)
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.
J Neurochem, 125 (3): 446-56. [PMID:23410232]